Based on this data, the clinical trial has been expanded to include a registration directed cohort of pts who have anti-PD1 failed cutaneous melanoma (125 pts) and pts with anti-PD1 failed non-small cell lung cancer, anti-PD1 failed MSI-H cancers and anti-PD1 failed NMSC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.